How do antifungals behave in septic shock? small study aims to find out
NCT ID NCT02805049
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 4 study looked at how the body processes echinocandin antifungal drugs (caspofungin or micafungin) in 24 adults with septic shock caused by peritonitis. Researchers measured drug levels in the blood to understand clearance, distribution, and concentration. The goal was to gather knowledge for better dosing, not to test a new treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Echinocandins (caspofungin or micafungin)
What this could lead to
If successful, this could help doctors better dose echinocandins for septic shock patients with abdominal infections, potentially improving treatment outcomes.
What could go wrong
This is a small, completed pharmacokinetic study with only 24 participants, so results may not apply broadly. It does not test whether the drugs improve survival or cure the infection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEPTIC SHOCK are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU de Nîmes - Hôpital Universitaire Carémeau
Nîmes, 30029, France
-
Royal Brisbane Women's Hospital
Herston, 4029, Australia